Last reviewed · How we verify

NCT03036410: PhoneCIHA

Evaluation of Different Phone Solutions in CI and Hearing Aid Users and Bimodal Recipients

Completed NA Last updated 7 September 2017
What this trial tests

NA trial testing standard telephone setting in Hearing Loss, Binaural in 25 participants. Completed in 21 August 2017.

Timeline
1 February 2017
Primary endpoint
21 August 2017
21 August 2017

Quick facts

Lead sponsorAdvanced Bionics AG
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment25
Start date1 February 2017
Primary completion21 August 2017
Estimated completion21 August 2017
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

Advanced Bionics AG — full company profile →

Who can join

Adults 18 to 80, any sex, with Hearing Loss, Binaural or Hearing Loss, Monaural. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Communication on telephone is challenging for people with hearing loss. For hearing aid users, for instance, the inventions for improving speech intelligibility on the phone range from an integrated tele coil and individual hearing programs to specially designed phone devices. No formal studies involving these devices have been carried out with CI users. Thus, this comparative study includes hearing aid as well as CI and bimodal users to evaluate different hearing solutions for communication on telephone in terms of intelligibility and ease of use.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Advanced Bionics AG trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03036410.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing